10-Q: Avalo Therapeutics Q3 2025 Loss: AVTX-009 Trial Progresses

Avalo Therapeutics reported a net loss of $64.5 million for the nine months ended September 30, 2025, but expects existing cash to fund operations into 2028, driven by progress in its AVTX-009 Phase 2 trial.

Summary

• A net loss of $64.5 million was incurred for the nine months ended September 30, 2025, compared to net income of $0.2 million for the same period in 2024.
• A net loss of $30.6 million was incurred for the three months ended September 30, 2025, compared to net income of $23.0 million for the same period in 2024.
• Cash and cash equivalents and short-term investments totaled $111.6 million as of September 30, 2025.
• Cash used in operating activities was $37.2 million for the nine months ended September 30, 2025.
• Research and development expenses increased by $20.6 million to $36.8 million for the nine months ended September 30, 2025, primarily due to the AVTX-009 Phase 2 LOTUS trial.
• General and administrative expenses increased by $4.4 million to $16.4 million for the nine months ended September 30, 2025, mainly due to stock-based compensation and headcount.
• Enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa (HS) was completed in October 2025.
• Topline results from the AVTX-009 Phase 2 LOTUS trial are expected in mid-2026.
• Existing cash and investments are sufficient to fund operations for at least twelve months from the filing date and into 2028.

Sentiment

Score: 4

Explanation: While the company has a solid cash runway and has achieved a key clinical milestone (enrollment completion), the significant increase in net loss and operating expenses, coupled with the negative shift in other income/expense, indicates a challenging financial performance. The reliance on future financing and the inherent risks of clinical development temper optimism, despite the progress on AVTX-009.

Positives

• Completed enrollment in the Phase 2 LOTUS trial for AVTX-009 in HS in October 2025, a significant development milestone.
• Existing cash and cash equivalents and short-term investments of $111.6 million are expected to fund operations into 2028, providing a solid runway.
• Appointment of Kevin Lind to the Board of Directors in September 2025 and expansion of the leadership team in October 2025.
• Unrealized income on investments, net, of $41 thousand for the nine months ended September 30, 2025.

Negatives

• Incurred a significant net loss of $64.5 million for the nine months ended September 30, 2025, a substantial increase from net income in the prior year.
• Negative cash flows from operations of $37.2 million for the nine months ended September 30, 2025.
• Substantial increase in research and development expenses ($20.6 million increase) and general and administrative expenses ($4.4 million increase) for the nine months ended September 30, 2025.
• Derivative liability increased significantly by $14.7 million for the nine months ended September 30, 2025, primarily due to changes in assumptions related to AVTX-007 Milestones and Royalties.
• Product revenue was zero for the three and nine months ended September 30, 2025, following the expiration of the Millipred license.

Risks

• Incurred significant operating and cash losses from operations since inception.
• No assurance that future financing or business development initiatives can be realized on favorable terms.
• Future equity sales will dilute existing stockholders' ownership and may include liquidation or other preferences.
• Raising funds through collaborations or licensing may require relinquishing valuable rights to technologies, revenue streams, or product candidates.
• No guarantee that products will obtain regulatory approval by the FDA or comparable foreign authorities; the approval process is complex, time-consuming, and expensive.
• FDA may impose post-approval requirements or withdraw approval if safety or efficacy issues arise.
• Research and development expenses beyond mid-2026 are difficult to predict and highly dependent on the outcome of the Phase 2 LOTUS trial.
• Valuation of derivative liability is based on unobservable inputs (probabilities of success, expected timing, forecasted sales) which could differ from actual outcomes and lead to significant changes in fair value.
• The company is not currently pursuing clinical development of quisovalimab (AVTX-002) and AVTX-006, and is exploring strategic alternatives, indicating potential for these assets to not generate future value.

Future Outlook

Avalo Therapeutics is focused on advancing its lead asset, AVTX-009, through the Phase 2 LOTUS trial for hidradenitis suppurativa, with topline results expected in mid-2026. The company plans to prepare for the next stage of development for this indication and consider further indication expansion for AVTX-009. It also aims to acquire or in-license targeted preclinical and clinical stage compounds for immune-mediated diseases and opportunistically out-license rights to existing compounds, indications, or geographies. Existing cash and investments are projected to fund operations into 2028.

Management Comments

• Our focus in 2025 is continuing to execute operationally on the development of AVTX-009, most notably the progression of the Phase 2 (LOTUS) trial of AVTX-009, an anti-IL-1 (mAb), in HS.
• We expect to release topline results from this trial in mid-2026.
• Management's primary evaluation of the success of the Company is the ability to progress its pipeline forward toward commercialization or opportunistically out-licensing rights to indications or geographies.
• We believe the ability to achieve the anticipated milestone as presented in the following chart represents our most immediate evaluation point as to the progress of our goal to move the pipeline forward.
• Based on our current operating plans, we expect that our existing cash and cash equivalents and short-term investments are sufficient to fund operations for at least twelve months from the filing date of this Quarterly Report on Form 10-Q and we expect to fund operations into 2028.

Industry Context

Avalo Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on IL-1-based treatments for immune-mediated inflammatory diseases. The successful completion of enrollment for its Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa is a critical step, as HS represents a significant unmet medical need. The company's strategy of advancing its lead asset while also exploring in-licensing and out-licensing opportunities is common among smaller biotechs seeking to manage risk and leverage assets. The significant increase in R&D expenses reflects the typical investment required to progress clinical trials in this industry. The positive development for AVTX-007 (out-licensed to Apollo) in atopic dermatitis, with peak annual net sales reaching $2.0 billion, highlights the potential value of successful drug development in large indications, even for non-core assets.

Comparison to Industry Standards

• The company's focus on IL-1-based treatments for immune-mediated inflammatory diseases aligns with a growing trend in immunology, where targeted therapies are increasingly sought after.
• The Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) targets a market with significant unmet needs, similar to other companies developing novel treatments for chronic inflammatory conditions. For example, AbbVie's Humira (adalimumab) and Johnson & Johnson's Stelara (ustekinumab) have been successful in HS, but there's still room for differentiated therapies.
• The reported probability of success for AVTX-007 (out-licensed to Apollo) in atopic dermatitis at approximately 41% for Phase 2a is within the typical range for early-to-mid-stage clinical assets in dermatology, though higher than average for Phase 1. Peak annual net sales reaching $2.0 billion in atopic dermatitis, if achieved, would place it among leading therapies like Dupixent (dupilumab) from Regeneron/Sanofi, which has achieved multi-billion dollar sales.
• The cash runway into 2028, following a net loss of $64.5 million for nine months, is a relatively strong position for a clinical-stage biotech, providing stability for ongoing trials compared to many peers who often face shorter runways and more frequent capital raises.

Management Changes

Corporate Governance

Legal Proceedings

• The company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. Reserves are established when a loss is probable and estimable.
• Currently, the company does not believe the resolution of such matters will have a material adverse effect on its financial position or results of operations, except as otherwise disclosed.

Related Party Transactions

• In the fourth quarter of 2022, Avalo sold economic rights to future milestone and royalty payments for AVTX-501, AVTX-007, and AVTX-611 to ES Therapeutics, LLC (ES), an affiliate of Armistice Capital LLC. Armistice was a significant stockholder, and its chief investment officer and managing director served on Avalo's Board until August 8, 2022. The transaction was approved in accordance with Avalo's related party transaction policy.
• On June 9, 2021, the company assigned its rights for AVTX-406 to ES Therapeutics, LLC, an affiliate of Armistice, which was a significant stockholder. This transaction was also approved in accordance with Avalo's related party transaction policy.
• In July 2019, Aevi (acquired by Avalo) entered into a royalty agreement with certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil (current CEO and former Chairman) and Mike Cola (former CEO), for a low-single digit percentage of net sales of AVTX-006 in exchange for a $2.0 million payment. This obligation is recorded as a royalty obligation.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings (ATM program, other equity sales) and equity compensation plans (2016 Fourth Amended Plan, ESPP, 2025 Inducement Award Plan). The significant net loss and cash burn could negatively impact share value, while progress in the AVTX-009 trial and a long cash runway provide some stability.
• Employees: Beneficiaries of stock-based compensation plans (stock options, RSUs, PSUs, ESPP), which can incentivize performance and retention. New inducement grants are specifically for new hires.
• Customers (future): Potential for new IL-1-based treatments for immune-mediated inflammatory diseases, particularly AVTX-009 for hidradenitis suppurativa, addressing unmet medical needs.
• Creditors: The company's cash runway into 2028 and ongoing efforts to secure financing mitigate immediate liquidity concerns.
• Licensing Partners (Lilly, Leap, KKC, CHOP, Astellas, Alto, AUG, Apollo): The company's strategic decisions regarding development and commercialization of licensed assets directly impact potential milestone and royalty payments to these partners. The positive Phase 2a results for AVTX-007 (Apollo) could lead to future payments to ES Therapeutics, which holds the economic rights.

Next Steps

• Release topline results from the Phase 2 LOTUS trial of AVTX-009 in HS in mid-2026.
• Prepare for the next stage of development for AVTX-009 in HS.
• Consider further indication expansion for AVTX-009.
• Explore opportunities to acquire or in-license targeted, complementary preclinical and clinical stage compounds for immune-mediated diseases.
• Opportunistically out-license rights to compounds, indications, or geographies.
• Monitor milestones and royalties for in-licensed and out-licensed compounds (AVTX-009, quisovalimab, AVTX-006, AVTX-301, AVTX-406, AVTX-800 Series).
• Evaluate the impact of adopting new accounting standards ASU 2025-07 and ASU 2024-03.

Key Dates

Recommendation

Avalo Therapeutics is a clinical-stage biotechnology company with a high-risk, high-reward profile. While the completion of enrollment for the AVTX-009 Phase 2 LOTUS trial is a significant operational milestone and the cash runway into 2028 provides stability, the company continues to incur substantial net losses and negative operating cash flows. The financial performance for the nine months ended September 30, 2025, shows a worsening trend compared to the prior year, largely due to increased R&D expenses for the lead asset and a negative shift in other income/expense. The stock's future performance is heavily dependent on the topline results of the AVTX-009 trial in mid-2026. Given the binary nature of clinical trial outcomes and the current financial burn, a 'hold' recommendation is appropriate for investors who are comfortable with the inherent risks of biotech and are awaiting key clinical data. Further capital raises are anticipated, which could lead to dilution.

Keywords

Biotechnology, Clinical Stage, IL-1, AVTX-009, Hidradenitis Suppurativa, HS, Phase 2 Trial, LOTUS Trial, Drug Development, SEC Filing, 10-Q, Financial Results, Biopharma, Immunology